Fact-checked by Grok 2 weeks ago

Bioelectronics

Bioelectronics is an interdisciplinary field that integrates principles from , , and to develop devices and systems interfacing directly with biological entities, ranging from molecules and s to tissues and organs. This interface enables the probing, monitoring, stimulation, and control of biological processes using electronic circuitry, with key components including biosensors, implantable devices, wearable electronics, and tools. Emerging from advances in soft materials, , and , bioelectronics addresses challenges such as , power supply limitations, and stable device-tissue interactions to facilitate applications in healthcare and beyond. The origins of bioelectronics trace back to the mid-20th century, coinciding with the invention of integrated circuits in the 1950s, which laid the groundwork for miniaturizing electronic components suitable for biological integration. Formal conceptualization emerged in the , with pioneering work by researchers like Göpel et al. in defining bioelectronics through the lens of biosensors and molecular recognition interfaces. Subsequent milestones, such as Willner et al.'s 2005 explorations of biomolecular electronics for and sensing, accelerated progress, particularly in the last 25 years driven by and biomaterials innovations. Central to bioelectronics are its applications in medical diagnostics and therapeutics, where devices like pacemakers, cochlear implants, and deep brain stimulators exemplify electronic control of physiological functions to treat conditions such as cardiac arrhythmias, , and . Wearable biosensors enable non-invasive, real-time monitoring of biomarkers in sweat or for glucose levels, electrolytes, and metabolites, supporting and remote health management. In bioelectronic medicine, implantable neural interfaces stimulate nerves or the to alleviate conditions such as and , with emerging potential for autoimmune disorders, offering targeted alternatives to pharmaceuticals with fewer side effects. Recent developments emphasize bioresorbable , which dissolve harmlessly in the after use, eliminating the need for surgical removal and enhancing safety for transient monitoring or therapy. Innovations in flexible materials, such as conducting polymers and graphene-based electrodes, improve long-term tissue compatibility and enable closed-loop systems that adjust therapies in based on physiological . As of 2025, further advancements include nonsurgical implants enabled by cell-electronics interfaces and bioelectronic actuators for in animal models. These advances position bioelectronics as a transformative force in addressing global healthcare challenges, including aging populations and chronic disease management, by bridging with biological complexity.

Introduction

Definition and Scope

Bioelectronics is defined as the interdisciplinary field that applies electronic principles to biological systems, primarily through the development of devices and interfaces that enable the sensing, actuation, or of biological processes. These interfaces facilitate the of signals between ionic and biochemical events in living tissues and electronic signals in devices, allowing for precise interaction at the molecular or cellular level. This encompasses the use of and semiconductors to create biocompatible systems that monitor physiological activities or intervene in them, such as detecting biomolecules or stimulating neural activity. The scope of bioelectronics is delineated by its emphasis on electronic-biological signal translation, distinguishing it from related domains. Bioelectronics focuses on electrical interfacing and with biological materials, while more broadly applies biological principles to the design of engineering systems, including mechanical prosthetics, biomimetic structures, and electronic devices such as cochlear implants, with notable overlap in areas like neural prosthetics. It differs from , a branch of electronics centered on light-emitting and light-detecting components for photon-based . Within its boundaries, bioelectronics includes adapted for biological environments, leveraging flexible, ionically conductive polymers to bridge the soft, aqueous nature of with rigid electronic hardware. Key terminology in bioelectronics highlights its specialized applications. "Bioelectronic medicine" denotes the convergence of , , and to create implantable or wearable devices that diagnose and treat diseases by targeting neural pathways with electrical , offering alternatives to pharmacological interventions. "Organic bioelectronics" specifically refers to the design of organic semiconductor-based devices that serve as transducers between biological ionic signals and electronic currents, enabling seamless integration with tissues due to their and mixed conductivity. "Hybrid bioelectronic systems" describe integrated platforms that merge living cellular components, such as engineered cells or tissues, with electronic elements to achieve augmented functionality, like self-regulating sensors or actuators. The term "bioelectronics" originated in the , coined in the context of early neural interface research exploring electrical stimulation of the , building on foundational studies of bioelectric phenomena such as action potentials. This etymology reflects the field's roots in applying electronics to understand and manipulate inherent electrical activities in biological systems, evolving from initial concepts of electron transfer in biomolecules proposed by in 1968.

Importance and Interdisciplinary Nature

Bioelectronics holds profound societal significance by enabling through real-time monitoring and targeted interventions tailored to individual physiological profiles. This approach facilitates chronic disease management, such as modulating inflammatory responses or neural activity to alleviate conditions like or without relying solely on pharmaceuticals. Furthermore, it supports human augmentation by enhancing sensory or cognitive functions, for instance, through neural interfaces that restore mobility in paralyzed individuals or regulate activity for support. The global bioelectronics market underscores this impact, estimated at approximately $10-17 billion in 2025 according to various analyses. The field's interdisciplinary nature integrates biology's understanding of cellular signaling with ' circuit design principles to create seamless interfaces between living tissues and synthetic systems. contributes biocompatible substrates that ensure long-term device stability and minimize immune rejection, while informs the development of implantable devices for precise therapeutic delivery. This convergence fosters collaborative advancements, as seen in organic bioelectronics where meets biosciences to engineer devices that mimic natural bioelectric processes. Broader implications extend to tackling challenges, including neurodegeneration and organ failure, where bioelectronic devices can stimulate neural circuits to slow disease progression or restore organ function via . Recent developments as of include AI-integrated closed-loop systems for real-time therapeutic adaptation. However, these developments raise ethical considerations, particularly around in neural , as implantable systems generate sensitive vulnerable to breaches or misuse without robust legal safeguards. Economic drivers further propel growth, with integrations of wearables and enabling for health outcomes and expanding market accessibility. This synergy is expected to accelerate adoption, potentially transforming healthcare delivery worldwide.

Historical Development

Early Foundations

The foundations of bioelectronics trace back to the late , when physician and physicist conducted pioneering experiments on , observing muscle contractions triggered by electrical sparks, which led him to propose the concept of "animal electricity" as an inherent property of living tissues. These findings, detailed in his 1791 treatise De Viribus Electricitatis in Motu Musculari Commentarius, demonstrated that electrical stimulation could elicit biological responses, laying the groundwork for understanding bioelectric signals. Building on Galvani's work, German physiologist advanced the study of bioelectricity in the 1840s by developing sensitive instruments to measure electrical potentials in nerves and muscles, confirming the existence of action currents during physiological processes. His 1848 book Untersuchungen über thierische Elektricität introduced quantitative methods for recording these potentials, establishing as a rigorous scientific discipline and highlighting the electrical nature of nerve impulses. In the early 20th century, British physiologist refined techniques for recording neural signals in the , using amplifiers to amplify and measure the all-or-nothing action potentials in single nerve fibers, which earned him the 1932 in Physiology or Medicine shared with Charles Sherrington. Concurrently, Dutch physiologist invented the string galvanometer in 1903, enabling the first practical (ECG) recordings of the heart's electrical activity, a breakthrough that also contributed to his 1924 . The mid-20th century saw conceptual bridges between electronics and biology through the field of , pioneered by American mathematician in his 1948 book Cybernetics: Or Control and Communication in the Animal and the Machine, which explored systems common to electronic devices and biological organisms for control and adaptation. Wiener's framework in the 1940s and 1950s emphasized how electronic circuits could model neural loops, influencing early ideas in bioelectronic interfaces. A pivotal early bioelectronic device emerged in 1958 with the invention of the first fully implantable by Swedish engineer and surgeon Åke Senning, which used transistor-based to deliver electrical pulses for heart rhythm regulation. Implanted successfully in a on October 8, 1958, this rechargeable device marked the initial fusion of with biological tissue for therapeutic purposes.

Key Milestones in the 20th and 21st Centuries

In the mid-20th century, bioelectronics advanced from theoretical concepts to practical devices with the pioneering work on cochlear implants. In 1957, French researchers André Djourno and Charles Eyriès performed the first implantation of an electrode into the auditory nerve of a deaf patient, eliciting auditory sensations through electrical stimulation and laying the groundwork for modern neural prostheses. This breakthrough was followed in the 1960s by further refinements, including William House's implantation of the first single-channel cochlear device in 1961, which demonstrated feasibility for restoring hearing in profoundly deaf individuals. The 1970s saw the emergence of additional neural prostheses, such as the first auditory brainstem implant in 1977 by William House and colleagues, which targeted the to bypass damaged auditory pathways and enable sound perception in patients with non-functional auditory nerves. The 1990s marked significant progress in materials and recording technologies essential for bioelectronic interfaces. Conductive polymers like poly(3,4-ethylenedioxythiophene) (PEDOT) emerged as biocompatible alternatives to rigid metals, with the monomer EDOT first synthesized in 1988 and PEDOT:PSS formulation developed shortly thereafter, enabling stable, flexible conduction in biological environments. Concurrently, the electrode array was invented in 1989 by Richard Normann at the , featuring a high-density silicon-based for intracortical neural recording and stimulation, which became a standard tool for brain-machine interfaces. Entering the and , bioelectronics integrated optical and flexible paradigms to enhance precision and adaptability. was introduced in 2005 through the work of and , who demonstrated millisecond-scale control of neural activity using light-sensitive ion channels like channelrhodopsin-2, revolutionizing targeted neural modulation and paving the way for hybrid optoelectronic devices. In the , flexible electronics advanced skin-interfaced bioelectronics, exemplified by 2010 developments of pressure-sensitive artificial electronic skins with human-like touch sensitivity, using or microstructure-based sensors on flexible substrates to conform to dynamic biological surfaces. The 2020s have witnessed the rise of biohybrid systems and regulatory milestones, expanding bioelectronics into regenerative and therapeutic domains. In 2022, researchers reported stretchable mesh integrated with developing for single-cell chronic recording, enabling long-term, stable monitoring of neural activity over months without disrupting organoid growth. Market-driven progress accelerated with FDA approvals for bioelectronic therapies, including the 2025 clearance of the SetPoint System stimulator for treating moderate-to-severe by modulating inflammatory responses through targeted electrical pulses.

Fundamental Principles

Bioelectric Phenomena

Bioelectric phenomena encompass the electrical signals generated by living organisms at cellular and tissue levels, arising from ion movements across membranes. At the cellular level, bioelectricity is fundamentally driven by ion channels, which are specialized proteins forming hydrophilic pores in cell membranes that permit the selective and rapid passage of ions such as Na⁺, K⁺, Ca²⁺, and Cl⁻ down their electrochemical gradients. These channels can be gated by voltage changes, ligands, or mechanical stimuli, enabling transport rates up to 10^8 ions per second, far exceeding those of carrier proteins. The resulting membrane potential, typically ranging from -20 mV to -200 mV at rest, is maintained by a balance of ion gradients established by pumps like the Na⁺-K⁺ ATPase and selective leak channels, predominantly for K⁺. The equilibrium potential for a specific ion, known as the Nernst potential, quantifies the voltage at which its electrochemical gradient is zero and is given by the Nernst equation: E = \frac{RT}{zF} \ln \left( \frac{[\ion_{\out}]}{[\ion_{\in}]} \right) where R is the gas constant, T is temperature in Kelvin, z is the ion's valence, F is Faraday's constant, and [\ion_{\out}] and [\ion_{\in}] are the extracellular and intracellular ion concentrations, respectively. This equation, derived from thermodynamic principles, underpins the resting membrane potential, which is closest to the K⁺ equilibrium potential due to high membrane permeability to K⁺. Action potentials represent dynamic bioelectric events crucial for signal propagation in excitable cells like neurons and muscle fibers. These transients occur when voltage-gated ion channels open in response to , leading to rapid influx of Na⁺ followed by K⁺ efflux. The seminal Hodgkin-Huxley model, developed from experiments on the , provides a quantitative description of this process by modeling membrane currents as functions of voltage and time-dependent gating variables. The core equation governing the change is: \frac{dV}{dt} = \frac{I - g_{\Na} m^3 h (V - E_{\Na}) - g_{\K} n^4 (V - E_{\K}) - g_{\L} (V - E_{\L})}{C_{\m}} where V is the membrane potential, I is the applied current, g_{\Na}, g_{\K}, and g_{\L} are maximum conductances for sodium, potassium, and leak currents, m, h, and n are activation/inactivation gating variables, E_{\Na}, E_{\K}, and E_{\L} are reversal potentials, and C_{\m} is membrane capacitance. This model elucidates how voltage-gated Na⁺ and K⁺ channels generate the characteristic rapid depolarization and repolarization phases of action potentials, enabling their all-or-none propagation. At the tissue level, synchronized cellular activity produces measurable extracellular bioelectric signals that reflect organ function. The electrocardiogram (ECG) captures cardiac bioelectricity through surface electrodes, recording potentials from 0.01 to 5 mV in the 0.05–250 Hz range, with features like the (atrial ), (ventricular ), and () providing diagnostic insights into arrhythmias and ischemia. Similarly, the electroencephalogram (EEG) detects neural activity via electrodes, yielding signals of 0.005–0.3 mV in the 0.1–80 Hz band, which reveal states from to . These tissue-level potentials arise from extracellular field effects of action potentials in aligned cell populations, such as cardiomyocytes or cortical neurons, and extend to other organs like the for gastric motility. Endogenous , generated by transepithelial transport and currents (1–100 μA/cm²), play pivotal roles in biological processes beyond excitability. In , these fields establish voltage gradients that guide embryonic patterning, , and organ formation, as seen in the polarity of limb buds and morphogenesis. During , injury disrupts epithelial barriers, creating fields that direct galvanotaxis of and fibroblasts toward the , accelerating reepithelialization by up to 40% in clinical settings. In regeneration, endogenous fields promote formation and tissue regrowth in species like salamanders, with current reversals correlating to proliferative phases; disrupting these fields impairs recovery in less regenerative organisms like mammals.

Principles of Electronic-Biological Interfaces

Electronic-biological interfaces in bioelectronics require careful to bridge the gap between conductive biological and circuits, ensuring efficient signal exchange without compromising tissue integrity. A primary challenge is , as biological tissues exhibit relatively low —typically on the order of 100–1000 Ω—compared to the higher input impedances of many amplifiers, which can lead to signal attenuation and noise if not addressed. To model this interface, the Randles is widely used, representing the electrode-electrolyte as a series combination of solution R_s and the parallel elements of charge transfer R_{ct} and double-layer C_{dl}, often expressed as Z = R_s + \frac{R_{ct}}{1 + j\omega R_{ct} C_{dl}} + W, where W accounts for diffusive impedance in some variants. This model facilitates the design of low-impedance interfaces, such as through surface modifications or buffer layers, to minimize mismatch and optimize power transfer. Signal transduction at these interfaces involves capturing weak bioelectric signals, such as action potentials, and processing them for electronic analysis. Amplification is achieved using low-noise operational amplifiers with high to preserve signal fidelity, followed by bandpass filtering to isolate relevant bands (e.g., 0.5–100 Hz for neural signals) and reject artifacts like motion noise.30807-2) occurs via analog-to-digital converters (ADCs), which sample the conditioned analog signal at rates exceeding the (typically 1–10 kHz for bio-signals) and quantize it into discrete levels, enabling digital processing while minimizing through anti-aliasing filters. Successive approximation register () ADCs are commonly employed in implantable devices due to their balance of resolution (8–16 bits) and power efficiency. For bidirectional interfaces, mechanisms deliver controlled electrical pulses to elicit biological responses, bounded by charge injection limits to prevent irreversible electrochemical reactions or damage. Charge is injected primarily through capacitive in reversible electrodes, with the charge Q = \int I(t) \, dt constrained by Shannon's model, which predicts safe limits of approximately 95 μC/cm² for electrodes at pulse durations around 0.2–100 μs to avoid faradaic processes leading to shifts or gas evolution. Biphasic waveforms are standard to maintain charge balance and minimize net , enhancing and . Feedback systems enable adaptive operation by incorporating sensed biological responses to modulate stimulation or recording parameters, accounting for inherent variability in tissue properties like impedance fluctuations due to inflammation or motion. Closed-loop control often adapts proportional-integral-derivative (PID) algorithms, where the error signal (e.g., deviation from target neural activity) drives proportional gain for immediate response, integral for steady-state elimination, and derivative for anticipating changes, tuned via methods like Ziegler-Nichols to handle nonlinear biological dynamics. In neural prosthetics, such systems achieve stable regulation, reducing overstimulation risks by 20–50% in variability-prone environments.

Materials and Technologies

Biocompatible Materials

Biocompatible materials in bioelectronics are essential for ensuring safe and effective interactions between electronic components and biological tissues, minimizing inflammatory responses and enabling long-term functionality. These materials must exhibit properties such as electrical conductivity, mechanical compliance with tissue moduli (typically 1–10 kPa), and adherence to international standards like for , , and implantation testing. Organic conductors, inorganic metals, hydrogels, and biodegradable polymers represent key classes, each tailored to reduce impedance at bioelectronic interfaces while promoting tissue integration. 2D materials, such as and carbon nanotubes, offer high conductivity (up to 10^6 S/cm for ) and flexibility for bioelectronic interfaces, with graphene-based electrodes demonstrating low impedance (<10 kΩ at 1 kHz) and enhanced biocompatibility in neural applications. Organic conductors, particularly poly(3,4-ethylenedioxythiophene):polystyrenesulfonate (PEDOT:PSS), are widely adopted due to their high electrical conductivity of approximately 1000 S/cm and inherent biocompatibility, which limits foreign-body reactions in neural and epidermal applications. This material's aqueous processability and mechanical flexibility (Young's modulus ~0.1–10 MPa, matching soft tissues) make it suitable for conformal coatings on electrodes. Complementary polymers like polyaniline (PANI) and polypyrrole (PPy) offer conductivities in the range of 10–100 S/cm and enhanced flexibility for strain-tolerant sensors, with PANI's pH-responsive doping enabling tunable electrochemical properties and PPy's biomimetic adhesion supporting stable tissue contacts. These conducting polymers reduce interfacial impedance to below 20 kΩ at 1 kHz, facilitating efficient charge transfer without delamination. Inorganic materials provide robust alternatives for high-charge-injection electrodes, with platinum-iridium (Pt-Ir) alloys favored for their corrosion resistance, per ISO 10993-5 implantation tests, and increased hardness (Vickers >500 at 50% Ir) compared to pure . These alloys support safe neural stimulation by enabling reversible charge injection up to 0.5 mC/cm² without gas evolution or damage. Silicon-based microelectromechanical systems () are often encapsulated with parylene-C coatings to achieve pinhole-free barriers (thickness 1–10 μm), enhancing by preventing ion leakage and while maintaining flexural rigidity below 1 GPa for implant integration. Hydrogels and natural polymers enable soft, hydrated interfaces that mimic extracellular matrices, with chitosan-based hydrogels demonstrating (cell viability >90% per ISO 10993-5) and mechanical tunability ( 0.1–5 kPa) for seamless bioelectronic . Alginate hydrogels complement this by offering ionic (~10 mS/cm) and low swelling ratios (<20% in physiological fluids), ideal for minimizing mechanical mismatch at tissue-device boundaries. Recent advances have developed oriented crystallization silk fibroin-based bioelectronic devices for high-sensitivity, stable, and prolonged recording, with electrical stability over 40 days in aqueous environments, reducing through its natural degradation profile. Biodegradable materials support transient bioelectronics that dissolve post-functionality, avoiding secondary surgeries, with poly(lactic-co-glycolic acid) (PLGA) polymers excelling due to tunable degradation rates (weeks to months via ) and compliance with ISO 10993-6 for local effects testing, showing no systemic toxicity in subcutaneous implants. 's encapsulation of active components enables controlled dissolution while preserving electrical performance, with degradation products metabolized harmlessly .

Fabrication Techniques

Fabrication techniques in bioelectronics focus on creating devices that seamlessly with biological tissues, requiring high precision at and nanoscale levels to ensure and functionality. These methods prioritize scalability for while maintaining the flexibility and softness needed for implants and sensors. Key approaches draw from processing and , adapted to handle biocompatible substrates like polymers and hydrogels. Microfabrication remains a cornerstone for producing rigid silicon-based neural arrays, where photolithography patterns photoresist on silicon wafers to define electrode sites, followed by etching—often deep reactive ion etching (DRIE)—to form sharp probes with feature sizes below 10 μm. This enables high-density electrode arrays for precise neural recording, as demonstrated in ultra-thin silicon probes achieving shank widths of 50 μm and lengths up to 5 mm. For flexible components, soft lithography uses PDMS molds replicated from SU-8 photoresist masters on silicon, allowing rapid prototyping of elastomeric channels and electrodes with resolutions down to 1 μm, ideal for conformable biointerfaces. Printing technologies enable low-cost, scalable deposition of organic conductors, such as for patterning PEDOT:PSS electrodes on flexible substrates with line widths as fine as 20 μm, supporting organic electrochemical transistors for biosensing. Screen printing complements this by applying thicker inks for robust , achieving conductivities up to 100 S/cm on large-area films. In , extrusion-based direct ink writing methods fabricate customizable transient bioelectronics and sensors using transient materials like poly(octamethylene maleate (anhydride) citrate), enabling features of 200–300 μm for biomechanical monitoring, as shown in 2024 developments that dissolve post-implantation. Assembly methods integrate fabricated components into functional devices, with wafer bonding joining silicon layers via anodic or adhesive techniques to create hermetic seals, reducing encapsulation thickness to under 10 μm for flexible implants. Encapsulation often employs parylene-C vapor deposition for conformal barriers against moisture, extending device lifetimes to over 1 year in physiological environments. Recent advancements in enable scalable fabrication of flexible bioelectronics, including continuous production of high-resolution lines on substrates for multilayer organic circuits. Post-fabrication, sterilization via gamma irradiation at 25-40 kGy ensures sterility without residues, maintaining conductivity in polymer electrodes like by minimizing chain scission. Compatibility testing includes cytotoxicity assays, such as ISO 10993-5 direct contact methods on L929 fibroblasts, confirming cell viabilities above 70% for encapsulated bioelectronic implants. These steps validate device safety before deployment.

Applications

Biosensors and Diagnostics

Biosensors in bioelectronics represent a class of devices that integrate biological elements with mechanisms to detect and quantify biological analytes or signals with high specificity and . These devices enable monitoring of physiological parameters, facilitating early diagnostics and personalized healthcare. By leveraging bioelectric phenomena at the between living tissues and , biosensors convert biochemical reactions into measurable electrical signals, such as or voltage changes. A foundational example is the enzymatic electrochemical glucose sensor, first conceptualized by and Lyons in 1962, which employs to catalyze the oxidation of glucose, producing whose subsequent electrochemical oxidation generates a current proportional to glucose concentration. This first-generation biosensor, often termed the electrode, laid the groundwork for continuous glucose monitoring systems used in . Modern iterations, such as Abbott's FreeStyle Libre, apply this principle in a minimally invasive wearable format, where a subcutaneous filament measures interstitial glucose levels every minute and transmits wirelessly to a reader or for up to 14 days. Wearable diagnostics have expanded beyond glucose to include non-invasive sweat analysis patches, which employ ion-selective electrodes to measure biomarkers like pH, electrolytes (e.g., sodium and ), and metabolites such as . In 2023, flexible electrochemical sweat sensors demonstrated real-time detection of these analytes during , offering insights into status and metabolic without the need for blood sampling. These patches typically feature microfluidic channels to collect and guide sweat to sensing electrodes, enabling continuous monitoring with minimal user intervention. Implantable monitors further advance diagnostics by providing long-term, internal tracking of bioelectric signals like electrocardiogram (ECG) and electroencephalogram (EEG) for cardiac and neurological . Devices such as bioelectronic implants these signals continuously to detect arrhythmias or seizures, with recent designs incorporating for remote data access. Key performance metrics for these biosensors include , quantified by the limit of detection (LOD), often achieving sub-nanomolar levels (e.g., <1 nM for cytokine detection) to capture trace analytes in complex biological matrices. Selectivity ensures minimal interference from non-target species, typically enhanced through specific biorecognition elements like antibodies or enzymes. Drift compensation algorithms, such as baseline correction or machine learning-based calibration, mitigate signal instability over time, maintaining accuracy during prolonged deployment. These metrics collectively enable reliable, point-of-care diagnostics with clinical-grade precision.

Therapeutic Devices and Implants

Therapeutic devices and implants in bioelectronics represent a class of active systems designed to modulate physiological functions for purposes, primarily through electrical or electromechanical of targeted tissues or organs. These devices deliver controlled electrical impulses to restore or regulate normal activity in dysfunctional systems, offering alternatives to pharmacological interventions with potentially fewer systemic side effects. Key examples include cardiac rhythm management tools and systems that address neurological disorders by interfacing directly with neural pathways. Implantable cardioverter-defibrillators (ICDs) exemplify early therapeutic bioelectronics for cardiac applications, with the first human implantation occurring in 1980 to prevent sudden cardiac death by detecting and terminating life-threatening arrhythmias through defibrillatory shocks. These devices monitor heart rhythm continuously and deliver tiered therapies, from pacing to high-energy shocks, significantly reducing mortality in high-risk patients. Similarly, stimulators (VNS) were approved by the FDA in 1997 as an adjunctive therapy for refractory , where they electrically stimulate the to reduce frequency by up to 50% in responsive patients through modulation of brainstem nuclei. Deep brain stimulation (DBS) systems utilize arrays implanted in subcortical targets, such as the subthalamic , to alleviate motor symptoms in advanced ; the FDA approved this application in 2002 based on clinical trials demonstrating sustained tremor reduction and improved . To ensure device longevity and , DBS employs charge-balanced biphasic pulses, which deliver equal positive and negative charges to neutralize net charge injection, thereby preventing corrosion and minimizing tissue damage from electrochemical reactions. In bioelectronic medicine, recent advancements include non-invasive ultrasound neuromodulation for hypertension management, with preclinical studies showing stimulation of the nucleus tractus solitarius achieving sustained reduction in hypertensive rat models by enhancing sensitivity. Long-term of such implants is enhanced through battery life optimization, often exceeding 10 years in low-power designs using integrated circuits that minimize during intermittent stimulation, as seen in cardiac and neuromodulation devices. Infection rates for these implants remain low, typically under 5%, due to sterile implantation protocols and biocompatible coatings that reduce bacterial adhesion.

Neural Interfaces and Prosthetics

Neural interfaces and prosthetics represent a core application of bioelectronics, enabling direct interaction between electronic systems and the to restore lost functions such as , hearing, and . These devices leverage bioelectric signals to decode neural intent or deliver targeted stimulation, facilitating brain-machine communication and sensory-motor augmentation. Invasive approaches embed electrodes within tissues for high-resolution signal acquisition, while non-invasive methods prioritize safety and accessibility, though with reduced fidelity. Advances in materials and algorithms have driven clinical translation, particularly for individuals with , sensory deficits, or amputations. Brain-computer interfaces (BCIs) exemplify neural interfaces by translating brain activity into actionable commands for external devices. Invasive BCIs, such as Neuralink's system, utilize ultrathin flexible threads equipped with 1,024 electrodes per array to record and stimulate neural activity at high bandwidth. Implanted via robotic surgery, these threads target cortical regions to decode motor intent, enabling users to control cursors or robotic limbs solely through thought; early human trials initiated in January 2024 following FDA approval in May 2023 have demonstrated cursor control and basic motor tasks in initial participants as of mid-2025. In contrast, non-invasive BCIs employ (EEG) caps to capture scalp-level signals, decoding or execution for prosthetic control without surgical risks. For instance, deep-learning algorithms like EEGNet achieve approximately 80% accuracy in real-time decoding of individual finger movements from EEG, allowing control of robotic hands in able-bodied users after brief training sessions. These decoding methods often rely on of event-related desynchronization in alpha and beta bands to infer intent, supporting applications in for motor-impaired individuals. Cochlear implants restore auditory function by bypassing damaged hair cells to directly stimulate the auditory nerve through multichannel electrode arrays inserted into the . Signal processing strategies, such as continuous interleaved sampling (CIS) or advanced combination encoders (ACE), decompose incoming into spectral bands, mapping them to temporal pulse patterns that mimic natural cochlear filtering for . These techniques enhance scores in noise by up to 50% compared to earlier analog methods, benefiting over one million users worldwide with severe-to-profound . Retinal implants address visual restoration in degenerative diseases like by electrically activating surviving retinal cells. A 2025 hybrid retinal prosthesis integrates a high-density array of 3,172 microelectrodes with human embryonic stem cell-derived neurons, enabling picocoulomb-level stimulation that triggers release to selectively engage bipolar cells and preserve ON/OFF pathway distinctions. In preclinical rat models, this design achieved 80% cell survival and induced axonal sprouting toward host tissue after 30 days, potentially supporting 20/40 resolution. Limb prosthetics incorporate bioelectronic control to achieve intuitive operation, primarily through myoelectric systems that detect electromyographic (EMG) signals from residual muscles via surface or implanted electrodes. Bipolar surface EMG electrodes capture amplitude-modulated signals proportional to force, enabling of prosthetic joints for tasks like grasping or walking; high-density EMG arrays further improve by multi-muscle patterns, reducing and enhancing locomotion mode recognition accuracy to 90-99%. Targeted muscle reinnervation (TMR), developed in 2002 as a nerve-transfer , redirects amputated nerve ends to denervated muscle targets in the residual limb, creating dedicated EMG sites for prosthetic control. This integration allows simultaneous multi-joint actuation—such as elbow flexion and hand grip—via algorithms, significantly improving functional outcomes in upper-limb amputees compared to conventional myoelectric setups. In human limb replantation, bioelectronic nerve guidance conduits aid post-surgical by bridging gaps and delivering electrical stimulation to promote axonal regrowth. These conduits, often incorporating conductive polymers or piezoelectric materials, provide a scaffold for migration and apply brief electrical pulses (e.g., 20 Hz for 1 hour daily) to upregulate growth factors like BDNF, accelerating sensory and motor reinnervation. Clinical trials in the using such stimulated conduits for peripheral repairs in replanted limbs reported sensory rates of approximately 80%, surpassing traditional suturing by enhancing functional reconnection in gaps up to 4 cm.

Challenges and Future Directions

Current Limitations and Reliability Issues

One major barrier in bioelectronics is , where implanted s often provoke a inflammatory response and from the host . This response involves the activation of immune cells, leading to the formation of a or fibrous capsule around the device, which isolates it and impairs between the electronics and biological s. Such reactions are exacerbated by mismatches between rigid device materials (with Young's moduli often exceeding 100 GPa) and soft neural s (1–100 kPa), causing ongoing irritation and damage. Additionally, degradation occurs due to biofluid and micromotion, resulting in increased impedance at the - , with changes exceeding 20% over six months in non-optimized systems, which reduces and recording . Reliability in bioelectronic devices is compromised by factors affecting long-term , particularly in flexible and stretchable formats. Recent analyses highlight mechanical fatigue at interconnects and soft-hard interfaces under physiological , where can occur after fewer than 10^6 flexural cycles in wearables or implants subjected to body motion. Battery longevity poses another challenge, as implantable systems typically last only 5–15 years before requiring replacement due to depletion or , while via RF or suffers from inefficiencies (e.g., fragile connectors in soft ) and inconsistent energy delivery in dynamic environments. These issues contribute to overall device failure rates, including and , underscoring the need for robust encapsulation to maintain electrical with less than 10% drift over one month. Scalability remains hindered by high development and deployment costs, with advanced neural implants like those from estimated at over $50,000 per unit when including surgical and insurance expenses. Regulatory hurdles further delay progress, as FDA Class III approvals for high-risk bioelectronic devices involve the Premarket Approval process, averaging 3–7 years from concept to market due to extensive clinical trials and safety evaluations. These timelines and costs limit widespread adoption, particularly for customized or experimental implants requiring specialized fabrication. Ethical and safety concerns in bioelectronics, especially brain-computer interfaces (BCIs), center on and potential physiological risks from electrical . BCIs generate sensitive neural data that is vulnerable to breaches, raising issues such as unauthorized access or "brainjacking," where hackers could manipulate thoughts or control device functions. During , unintended — the formation of pores in cell membranes—can occur as a side effect, leading to muscle contractions, nerve activation, or even irreversible and tissue damage like cardiac arrhythmias if fields exceed safe thresholds. Recent advancements in soft and biohybrid electronics are pushing the boundaries of bioelectronics toward more biologically integrated systems. In 2025, living neural interfaces have seen significant progress through organoid-on-chip platforms, which combine engineered brain organoids with microfluidic and electronic components to model neural diseases and enable electrophysiological monitoring. These systems facilitate dynamic interactions between living tissues and electronics, offering potential for personalized drug testing and regenerative therapies. Complementing this, stretchable electronic skins (e-skins) incorporating self-healing polymers have emerged as key innovations, demonstrating rapid recovery from mechanical damage—often within seconds—while maintaining conductivity and sensitivity under extreme deformation up to 700%. Such materials, often based on dynamic covalent bonds in polymer networks, enable durable, skin-like interfaces for long-term wearables. Non-invasive techniques are gaining traction for accessing deep tissues without surgical intervention, as outlined in 2025 roadmaps for . Ultrasound-based allows precise, focal of neural circuits at depths exceeding 10 cm, minimizing off-target effects compared to traditional electrical methods. Similarly, magnetic via (TMS) variants provides non-contact activation of regions, with recent protocols achieving sub-millisecond temporal resolution for therapeutic applications like . These approaches address prior reliability concerns by reducing implantation risks and enhancing patient compliance, paving the way for outpatient bioelectronic interventions. The integration of (AI) with bioelectronics is transforming brain-computer interfaces (BCIs) into adaptive systems capable of real-time signal decoding and personalization. algorithms, particularly models for , have improved BCI accuracy by up to 20% through in noisy neural data, enabling closed-loop feedback for motor restoration in neurological disorders. This synergy supports dynamic adaptation to user variability, such as signal drift over sessions. The global bioelectronics market, driven by these AI-enhanced devices, is projected to reach $33 billion by 2035, reflecting a of 12.87% from 2025 onward. Looking further ahead, regenerative bioelectronics holds promise for by merging conductive scaffolds with therapies to promote neural and muscular repair. Biohybrid systems, where electronics guide tissue growth via electrical cues, have demonstrated enhanced regeneration in preclinical models, potentially revolutionizing treatments for injuries. However, realizing this vision requires addressing global challenges, including equitable access in low-resource settings where infrastructure limitations and cost barriers hinder adoption. Strategies such as low-cost, solar-powered wearables and community-based deployment models are being explored to bridge these gaps and ensure broader societal benefits.

References

  1. [1]
  2. [2]
    Bioelectronics: The Path Here and the Journey to Come - PMC
    Dec 2, 2019 · The use of electronic materials to probe and control biological systems has grown enormously in recent years, with applications often being ...
  3. [3]
    [PDF] History of Bioelectronics: A review based on groundbreaking ...
    Bioelectronics devices can be used to diagnose, treat, and monitor numerous biological processes, such as biological signals, biological molecules, and.
  4. [4]
    The rise of bioelectronic medicine - BioMed Central
    Aug 21, 2024 · Bioelectronic Medicine (BEM), which uses implantable electronic medical devices to interface with electrically active tissues, aspires to revolutionize the way ...
  5. [5]
    Introduction to BioelectronicsMaterials, Devices, and Applications
    Bioelectronics is the field that involves the development of electronic interfaces with main objective to monitor or modulate biological processes.
  6. [6]
    Nano-Bioelectronics - PMC - PubMed Central
    Bioelectronics can be broadly defined as the merger of electronics with biological systems, where a bioelectronic device transduces signals from the ...
  7. [7]
  8. [8]
    Bioelectronics - Fleming - Major Reference Works
    Mar 15, 2010 · We define bioelectronics as the interfacing of naturally occurring or synthetic biological materials with inorganic electronic materials, ...
  9. [9]
    What You Should Know About Optoelectronics - Spark Innovations
    Optoelectronics is a branch of electronics that is specifically concentrated on light-emitting or light-detecting devices.
  10. [10]
    Organic Bioelectronics: Bridging the Signaling Gap between Biology ...
    Jul 1, 2016 · Organic bioelectronics comprises the development and studies of organic electronic devices that operate as translators between the signals and functions of ...
  11. [11]
    Bioelectronic medicine: technology targeting molecular mechanisms ...
    Bioelectronic medicine, the convergence of molecular medicine, neuroscience, engineering and computing to develop devices to diagnose and treat diseases.
  12. [12]
    Bio-hybrid electronic and photonic devices - PMC - PubMed Central
    Dec 19, 2022 · Bio-hybrid devices, combining electronic and photonic components with cells, tissues, and organs, hold potential for advancing our understanding of biology.
  13. [13]
    Bioelectronic Medicine 2019-2029 - IDTechEx
    Electrical neuromodulation began in the 1960s with the development of stimulators for the central nervous system. The spinal cord and areas of the brain were ...
  14. [14]
    What is bioelectronics? (Chapter 1)
    Bioelectronics is a field establishing synergy between electronics and biology, focusing on the interface between biological materials and electronics.
  15. [15]
    Flexible self-powered bioelectronics enables personalized health ...
    Jul 30, 2024 · Bioelectronic devices play a crucial role in establishing a human-machine interface (HMI) for real-time monitoring of human physiological ...
  16. [16]
    (PDF) Bioelectronic Medicines for Chronic Disease Management
    Aug 5, 2024 · This paper explores the historical development, underlying principles, biological basis, and clinical applications of bioelectronic medicines.Missing: personalized augmentation
  17. [17]
    How bioelectronics could heal our bodies and minds, with Bozhi Tian
    Jan 23, 2025 · Scientists design living devices to fight infections, power the heart and regulate the brain.
  18. [18]
    Bioelectronics Charting Growth Trajectories: Analysis and Forecasts ...
    Rating 4.8 (1,980) Jul 30, 2025 · The global bioelectronics market is experiencing robust growth, projected to reach \$16.9 billion in 2025 and maintain a Compound Annual ...
  19. [19]
    The rise of bioelectronic medicine - PMC - NIH
    Aug 21, 2024 · Bioelectronic Medicine (BEM), which uses implantable electronic medical devices to interface with electrically active tissues, aspires to revolutionize the way ...
  20. [20]
    Organic Bioelectronics: Diversity of Electronics Along with Biosciences
    Interdisciplinary Collaborations. Organic bioelectronics intersects with biology, electrical engineering, materials science, and medicine, necessitating the ...
  21. [21]
    Focus on bioelectronics: Cell Reports Physical Science
    Aug 21, 2024 · Bioelectronics broadly addresses the interface between biological systems and electronics, covering topics including, but not limited to, biosensors, ...
  22. [22]
    Bioelectronic medicine: Preclinical insights and clinical advances
    Nov 2, 2022 · The clinical utilization of bioelectronic modalities in treating inflammatory, cardiovascular, and neurodegenerative diseases, spinal cord ...
  23. [23]
    Harnessing the Therapeutic Potential of Neural Implants
    Bioelectric medicine leverages natural signaling pathways in the nervous system to counteract organ dysfunction. This novel approach has potential to address ...
  24. [24]
    Regulating neural data processing in the age of BCIs
    Mar 28, 2025 · This article notes that most of the current data laws like GDPR have not covered neural data clearly, incapable of providing full protection in response to its ...
  25. [25]
    AI-Driven Wearable Bioelectronics in Digital Healthcare - PMC - NIH
    AI-driven wearable bioelectronics use AI and sensors for real-time monitoring of physiological parameters, enabling early disease detection and personalized ...
  26. [26]
    Bioelectronics Market Size, Share, Trends & Insights Report, 2035
    The bioelectronics market size is projected to grow from USD 9.86 billion in 2025 to USD 33.09 billion by 2035, representing a CAGR of 12.873%, ...
  27. [27]
    Luigi Galvani's path to animal electricity - ScienceDirect.com
    Galvani carried out the experiments with artificial electricity from November 1780 up to February 1783, and he passed to the investigation of the effects of ...
  28. [28]
    Animal Electricity, circa 1781 | The Scientist
    Sep 28, 2011 · In the mid-1780s, Italian physician Luigi Galvani connected the nerves of a recently dead frog to a long metal wire and pointed it toward the ...
  29. [29]
    The Body Electric, 1840s | The Scientist
    Oct 31, 2014 · Emil du Bois-Reymond's innovations for recording electrical signals from living tissue set the stage for today's neural monitoring techniques.Missing: primary source
  30. [30]
    Emil du Bois-Reymond and Dom Pedro II - NIH
    Nov 24, 2022 · Emile Du Bois-Reymond pioneered scientific electrophysiology in parallel with 19th-century studies on various electric fish that underlie the great development ...Missing: bioelectric source
  31. [31]
    Edgar Adrian – Facts - NobelPrize.org
    Edgar Adrian developed methods for measuring electrical signals in the nervous system, and in 1928 he found that these always have a certain size.Missing: recordings 1920s
  32. [32]
    Einthoven's String Galvanometer: The First Electrocardiograph - PMC
    In developing the electrocardiograph, Einthoven built on the work of earlier physiologists who had studied the electrical mechanisms of the heart. Each earlier ...Missing: source | Show results with:source
  33. [33]
    [PDF] Cybernetics - MIT
    Norbert Wiener founded the field with his in his 1948 book Cybernetics: or Control and. Communication in the Animal and the Machine which articulated the ...
  34. [34]
    A brief history of cardiac pacing - PMC - PubMed Central
    Senning recounts: “On the 8th October 1958, in the evening, when there were no extra people in the theatre, I implanted the first pacemaker, but it lasted only ...
  35. [35]
    Rune Elmqvist: Inkjet Printers, Implantable Pacemakers
    Aug 28, 2025 · One of Elmqvist's other inventions could and did: the first fully implantable, rechargeable pacemaker. ... 1958, Senning placed the pacemaker ...
  36. [36]
    The evolution of cochlear implant technology and its clinical relevance
    In 1957, André Djourno and Charles Eyriès, the first one a professor of medical physics and the second one a Parisian otologist, tried to restore the facial ...
  37. [37]
    The History of the Cochlear Implant - Envoy Medical
    May 30, 2024 · Frenchmen André Djourno, an electrophysiologist, and Dr. Charles Eyriès, otolaryngologist, were inspired by the idea that electrical ...
  38. [38]
    Neuroprosthetics: from sensorimotor to cognitive disorders - Nature
    Jan 6, 2023 · The term neuroprosthesis itself was first coined in the scientific literature in 1971 to refer to an intraspinal implant that allowed bladder ...Missing: 1970s | Show results with:1970s<|separator|>
  39. [39]
    Recent Progress on PEDOT-Based Thermoelectric Materials - PMC
    The synthesis of PEDOT was first reported in 1988 [17]. It was designed and synthesized as a conducting polymer that is stable toward moisture and oxygen; ...2. Basis Of The Pedot System... · 4. Te Performance Of Pedot... · 6. Te Module Designing And...
  40. [40]
    Our Story | Blackrock Neurotech
    1989. The invention of the Utah Array · 2002. Monkeys control computer cursor · 2004. Utah Array is implanted in humans · 2008. Blackrock Microsystems is founded.
  41. [41]
    Bio-inspired electronics: Soft, biohybrid, and “living” neural interfaces
    Feb 21, 2025 · This review maps the field of bio-inspired electronics and discusses key recent developments in tissue-like and regenerative bioelectronics.Missing: history | Show results with:history
  42. [42]
    SetPoint Medical Receives FDA Approval for Novel Neuroimmune ...
    Jul 31, 2025 · The company's FDA-approved SetPoint System is the first neuroimmune modulation therapy available for people living with rheumatoid arthritis (RA) ...Missing: bioelectronic 2020s
  43. [43]
    Ion Channels and the Electrical Properties of Membranes - NCBI - NIH
    By making the plasma membrane much more permeable to K+ than to other ions, they have a crucial role in maintaining the membrane potential across all plasma ...
  44. [44]
    A quantitative description of membrane current and its application to ...
    HODGKIN A. L., HUXLEY A. F. Currents carried by sodium and potassium ions through the membrane of the giant axon of Loligo. J Physiol. 1952 Apr;116(4):449–472.
  45. [45]
    Advanced Bioelectrical Signal Processing Methods: Past, Present ...
    This paper presents an extensive literature review of the methods for the digital signal processing of cardiac bioelectrical signals that are commonly applied ...
  46. [46]
    A Systematic Review of the Role of Bioelectricity in Wound Healing ...
    Natural endogenous voltage gradients not only predict and correlate with growth and development but also drive wound healing and regeneration processes.
  47. [47]
    Bioelectrical Impedance Methods for Noninvasive Health Monitoring
    Under the alternating electrical excitation, biological tissues produce a complex electrical impedance which depends on tissue composition, structures, health ...Missing: biointerfaces | Show results with:biointerfaces<|control11|><|separator|>
  48. [48]
    Electrochemical Impedance Spectroscopy A Tutorial
    This tutorial provides the theoretical background, the principles, and applications of Electrochemical Impedance Spectroscopy (EIS) in various research and ...
  49. [49]
    Impedance Characterization & Modeling of Biomedical Electrodes
    Aug 6, 2025 · A low electrode-electrolyte impedance interface is critical in the design of electrodes for biomedical applications. To design low-impedance ...
  50. [50]
    Electronics and biological signal processing - PMC - NIH
    Biological signal processing involves amplifying outputs from electrodes/transducers, using filters, and converting signals to digital, with processing in ...Missing: transduction | Show results with:transduction
  51. [51]
    [PDF] Section 8: ADCs for Signal Conditioning - Analog Devices
    ADCs for signal conditioning include successive approximation (up to 16-bits), sigma-delta (up to 24-bits), and flash converters.Missing: transduction bioelectronic
  52. [52]
    A model of safe levels for electrical stimulation - IEEE Xplore
    Apr 30, 1992 · Abstract: A model that represents a large body of data on safety and damage levels of electrical stimulation is presented.
  53. [53]
    Tissue damage thresholds during therapeutic electrical stimulation
    Shannon equation. Shannon described the boundary between tissue damaging and non-damaging levels of electrical stimulation reported by McCreery et al (1990) on ...
  54. [54]
    Design of Closed-Loop Control Schemes Based on the GA-PID and ...
    Nov 15, 2023 · The present work proposes two closed-loop control schemes based on the improved incremental proportional integral derivative (PID) algorithms to modulate brain ...
  55. [55]
    Merging machine learning and bioelectronics for closed-loop control ...
    Aug 16, 2023 · We propose that machine learning can significantly enhance the capabilities of bioelectronics by facilitating real-time processing of sensor and actuator data.
  56. [56]
    ISO 10993-1:2018 - Biological evaluation of medical devices — Part 1
    In stock 2–5 day deliveryThis document specifies the general principles governing the biological evaluation of medical devices within a risk management process.
  57. [57]
    PEDOT:PSS-based bioelectronics for brain monitoring and modulation
    May 13, 2025 · This review comprehensively examines recent advances in the development of PEDOT:PSS-based bioelectrodes for brain monitoring and modulation.
  58. [58]
    Biocompatible Conductive Polymers with High Conductivity and High Stretchability
    ### Summary of PEDOT:PSS Conductivity and Biocompatibility with d-Sorbitol
  59. [59]
    Organic Bioelectronics for In Vitro Systems | Chemical Reviews
    Dec 15, 2021 · Polyaniline (PANI) and polypyrrole (PPy) represent two of the very first CPs reported to exhibit semiconducting properties. (72,73) ...
  60. [60]
    Electrochemical and biological performance of hierarchical platinum ...
    Sep 2, 2022 · Platinum-iridium alloy (Pt-Ir), with its excellent biocompatibility and corrosion resistance, has been widely used in implanted neural ...
  61. [61]
    Techniques and Considerations in the Microfabrication of Parylene ...
    Parylene C is a promising material for constructing flexible, biocompatible and corrosion-resistant microelectromechanical systems (MEMS) devices.
  62. [62]
    Chitosan-Based Hydrogels for Bioelectronic Sensing - NIH
    Jan 6, 2023 · Chitosan-based hydrogels exhibit the advantages of flexibility, biocompatibility, mechanical tunability, and stimuli sensitivity, and could serve as an ...
  63. [63]
    Hydrogel–Tissue Interface Interactions for Implantable Flexible ...
    Sep 16, 2022 · Hydrogels have emerged as multifunctional interface materials between implantable bioelectronic devices and biotissues.
  64. [64]
    Silk fibroin-based bioelectronic devices for high-sensitivity, stable ...
    Jan 1, 2025 · In this study, we developed a novel approach by creating oriented crystallization (OC) silk fibroin through physical modification of the silk protein.
  65. [65]
    Biodegradable Polymeric Materials in Degradable Electronic Devices
    This review surveys recent trends in the chemistry and engineering strategies used to make biodegradable polymer substrates, insulators, conductors, and ...Introduction · Common Chemistries Used for... · Biodegradable Polymeric...
  66. [66]
    Silicon microfabrication technologies for biology integrated advance ...
    Oct 1, 2023 · This review will describe the ubiquity of microfabrication techniques in biological systems through cell sensing, neural probes, and integrated/multiplexed ...
  67. [67]
    [PDF] Fabrication of neural probes from ultra-thin silicon - Caltech
    Jun 23, 2009 · Deep reactive ion etching was employed to create sharp implantable shafts with lengths of up to 5 mm. The devices were flip-chip bonded onto ...
  68. [68]
    Single-Step Transfer-Printing Microfabrication of Soft Bioelectronics ...
    May 3, 2023 · This process provides a complete set of efficient microfabrication procedures for soft bioelectronics, from metal deposition to patterning and ...Missing: lithography | Show results with:lithography
  69. [69]
    (PDF) Inkjet printed electrodes for organic bioelectronics applications
    This study reports on the fabrication of biocompatible organic devices by means of inkjet printing with a novel combination of materials. The devices were ...References (0) · Recommended Publications · P-122: Solution-Processed...
  70. [70]
    Organic Electrochemical Transistors: From Lithography to Large ...
    Oct 16, 2024 · The processing steps of screen-printed OECT involve the preparation of ink, coating printing, drying, and curing. Its fabrication process relies ...
  71. [71]
    3D Printing of Customizable Transient Bioelectronics and Sensors
    Jun 26, 2024 · This study introduces a fully digital 3D printing approach enabling the prototyping and customization of soft bioelectronics made of transient materials.
  72. [72]
    Recent Advances in Encapsulation of Flexible Bioelectronic ...
    Mar 30, 2022 · Wafer-bond encapsulation can be performed through several diverse techniques: silicon fusion bonding,[118, 119] intermediate layer bonding of ...
  73. [73]
  74. [74]
    Effective gamma-ray sterilization and characterization of conductive ...
    Feb 27, 2018 · Herein we describe the first study on gamma-ray sterilization of PPy bioelectrodes and its effects on their characteristics.Missing: bioelectronics | Show results with:bioelectronics
  75. [75]
    Electrochemical Glucose Sensors—Developments Using ... - MDPI
    In 1962, Clark and Lyons proposed incorporating the enzyme glucose oxidase in the construction of an electrochemical sensor for glucose in blood plasma.
  76. [76]
    FreeStyle Libre Continuous Glucose Monitoring | FreeStyle Libre US
    The FreeStyle Libre 3 Plus sensor lets you see your glucose levels in real time so you can make more confident choices 1 and lower your A1C.Cost & Coverage · FreeStyle Libre 3 · Libre 2 · Try for Free♢ with MyFreeStyle
  77. [77]
    Wearable and flexible electrochemical sensors for sweat analysis
    Jan 1, 2023 · Flexible wearable sweat sensors allow continuous, real-time, noninvasive detection of sweat analytes, provide insight into human physiology ...
  78. [78]
    Bioelectronic Implantable Devices for Physiological Signal ...
    Jul 8, 2024 · Bioelectronic implantable devices are adept at facilitating continuous monitoring of health and enabling the early detection of diseases.<|separator|>
  79. [79]
    Multiplex On-Chip Immunosensor for Advancing Inflammation ...
    Aug 27, 2025 · In this work, we developed an advanced electrochemical multiplex immunosensor platform using gold micro-electrodes modified by the ...
  80. [80]
    Recent Advances in Electrochemical Sensors for the Detection of ...
    Electrochemical sensors have emerged as powerful analytical tools for the detection of anti-inflammatory and antibiotic drugs due to their high sensitivity, ...
  81. [81]
    Addressing the Selectivity of Enzyme Biosensors - PMC - NIH
    The enzymatic biosensors take advantage of the enzymes' natural sensitivity and selectivity to achieve fast detection of either the substrate or inhibitor.
  82. [82]
    Detection principles of biological and chemical FET sensors
    Dec 15, 2017 · By measuring this leakage, the drift could be at least partially predicted and compensated. ... sensitivity limits of nanobiosensors using ...Missing: metrics | Show results with:metrics
  83. [83]
    Implantable cardioverter defibrillators – the past, present and future
    Jul 11, 2020 · ICDs have come a long way since their first implantation in humans in 1980, firmly cementing their place in preventing SCD. Despite four decades ...
  84. [84]
    P970003 - Premarket Approval (PMA) - FDA
    VNS THERAPY SYSTEM · STIMULATOR, AUTONOMIC NERVE, IMPLANTED FOR EPILEPSY · LivaNova USA, Inc. 100 Cyberonics Blvd. Houston, TX 77058 · P970003 · 01/27/1997.
  85. [85]
    Evolution of the Vagus Nerve Stimulation (VNS) Therapy System ...
    The VNS Therapy received FDA approval in 1997 for use as an adjunctive therapy in reducing the frequency of partial onset seizures which are refractory to ...
  86. [86]
    Deep brain stimulation (DBS) for the treatment of Parkinson's ...
    Dec 3, 2024 · Based on results from a large, multisite clinical trial, the FDA approved DBS in the STN or GPi to treat motor symptoms in advanced PD in 2002.Missing: arrays | Show results with:arrays
  87. [87]
    Modified Pulse Shapes for Effective Neural Stimulation - PMC
    Sep 28, 2011 · A biphasic, charge-balanced pulse prevents net charge injection into the stimulated tissue. Charge balancing is therefore a necessary ...
  88. [88]
    A scoping review of neuromodulation techniques for controlling ...
    Aug 15, 2025 · Non-invasive ultrasound modulation of solitary tract nucleus exerts a sustainable antihypertensive effect in spontaneously hypertensive rats.
  89. [89]
    Powering Implantable and Ingestible Electronics - PMC - NIH
    Devices that require relatively low power, such as pacemakers (10–30 μW) and artificial urinary sphincters (200 μW), can last for 8–12 years before they require ...
  90. [90]
    Association of the Timing and Extent of Cardiac Implantable ...
    Apr 5, 2023 · The estimated incidence of CIED infections ranges between 1% and 2% for all procedures and varies with procedure type.
  91. [91]
    Neuralink and Brain–Computer Interface—Exciting Times for ... - PMC
    Apr 15, 2024 · Neuralink has finally received approval from US FDA (May 2023) to initiate their trials that will implant these chips into humans.
  92. [92]
    EEG-based brain-computer interface enables real-time robotic hand ...
    Jun 30, 2025 · In this study, we present a real-time noninvasive robotic control system using movement execution (ME) and motor imagery (MI) of individual finger movements.
  93. [93]
    A Hundred Ways to Encode Sound Signals for Cochlear Implants
    May 1, 2025 · Cochlear implants are the most successful neural prostheses used to restore hearing in severe-to-profound hearing-impaired individuals.
  94. [94]
    Towards High‐Acuity Vision Restoration: Hybrid Retinal Prosthesis ...
    Sep 7, 2025 · This work introduces a novel Hybrid Retinal Implant (HRI), composed of a high-density electrode array integrated with glutamatergic neurons ...Missing: opto- | Show results with:opto-
  95. [95]
    Myoelectric control of robotic lower limb prostheses - PubMed Central
    A majority of existing studies on myoelectric control of lower limb prostheses have used bipolar surface EMG electrodes to record neuromuscular control signals.
  96. [96]
    Targeted Muscle Reinnervation and Advanced Prosthetic Arms - PMC
    Targeted muscle reinnervation (TMR) is a surgical nerve-transfer procedure, developed to provide amputees with more intuitive control of upper limb prostheses.
  97. [97]
    Does Electrical Stimulation through Nerve Conduits Improve ...
    Feb 26, 2023 · Conclusion: Electrically stimulated conduits could improve peripheral nerve regeneration in rat models. The combined application of nerve ...Missing: bioelectronic | Show results with:bioelectronic
  98. [98]
    Nerve conduits for treating peripheral nerve injuries: A systematic ...
    Use of nerve conduits is preferable over suture repair and nerve grafting, as the functional recovery rates are above 80%.Missing: limb 2010s
  99. [99]
  100. [100]
    Reliability and stability of Bioelectronic Medicine - PubMed Central
    Jul 12, 2025 · Bioelectronic Medicine relies on wearable or implantable electronic devices interfacing with the nervous system and other active tissues, ...
  101. [101]
    Mechanical fatigue of flexible batteries - AIP Publishing
    Sep 2, 2025 · One of the typical operational limitations of flexible electronics under bending or tensile fatigue loadings is the reliability issue.
  102. [102]
    Elon Musk's Neuralink Found Its First Patient — What It Could Cost if ...
    Apr 9, 2024 · The cost to insurers is expected to push the price up to $50,000. The actual price could easily run higher if the cost of necessary components, ...
  103. [103]
    Medical Device FDA Approval Process [+Timeline] - Greenlight Guru
    Nov 18, 2024 · All class III medical devices must go through the Premarket Approval (PMA) process, which takes at least 180 days for FDA approval. These are, ...
  104. [104]
    Drugs, Devices, and the FDA: Part 1: An Overview of Approval ...
    Apr 25, 2016 · New drug and device approval in the United States take an average of 12 and 7 years, respectively, from pre-clinical testing to approval. Costs ...
  105. [105]
    Ethical considerations for the use of brain–computer interfaces for ...
    Oct 28, 2024 · Erosion of privacy: To what extent does widespread use of eBCIs raise the risk of privacy erosion, such as thought violation or “brainjacking” ...
  106. [106]
    The emerging safety and ethical landscape of Brain-Computer ...
    Sep 26, 2024 · A crucial concern highlighted in the report is the issue of privacy and data security: BCIs can collect and potentially transmit sensitive ...
  107. [107]
    Effects of different applied voltages of irreversible electroporation on ...
    Dec 26, 2022 · Third, though IRE carries a risk of cardiac arrhythmias due to muscle contraction induced by electrical stimulation of excitable cells in the ...Missing: bioelectronics | Show results with:bioelectronics
  108. [108]
    Electrical Stimulation of Cells: Drivers, Technology, and Effects
    Jul 17, 2025 · Different metrics are used to characterize electrode performance, including impedance, and charge injection and storage capacity, while the ...
  109. [109]
    Review paper Brain organoids-on-chip for neural diseases modeling
    Apr 30, 2025 · Brain organoid-on-chip platforms have emerged as groundbreaking tools in neural disease modeling and drug discovery, offering a unique and highly accurate ...
  110. [110]
    Advances in bioelectronics for neural interfacing
    Oct 7, 2025 · Neural interfacing technologies aim at establishing seamless and stable communication between manmade devices and native neural tissues to ...
  111. [111]
    Rapidly self-healing electronic skin for machine learning–assisted ...
    Feb 12, 2025 · The E-Skin recovers more than 80% of its functionality within 10 seconds after physical damage, without the need of external stimuli.
  112. [112]
    Self-healing materials for wearable electronics - ScienceDirect.com
    Sep 25, 2025 · Flexible wearable devices are mainly composed of polymer film, which can be bent, folded, twisted, compressed, stretched and even deformed into ...
  113. [113]
    Bioelectronic Medicine: a multidisciplinary roadmap from biophysics ...
    It consists of the modulation of the nervous system by precise delivery of electrical current for the treatment of clinical conditions, such as post-stroke ...Bioelectronic medicine (M. A... · Glial cells and... · Big data, networks, and AI in...
  114. [114]
    Next generation bioelectronic medicine: making the case for non ...
    Jan 21, 2025 · The field of bioelectronic medicine has advanced rapidly from rudimentary electrical therapies to cutting-edge closed-loop systems that integrate real-time ...
  115. [115]
    New Paper Creates Roadmap for the Next Generation of ...
    Jan 21, 2025 · More recent developments have included noninvasive techniques, in which the nervous system can be stimulated by devices from outside of the body ...Missing: ultrasound tissue access
  116. [116]
  117. [117]
  118. [118]
    Smart bioelectronic materials and systems for regenerative tissue ...
    In this review, we provide a comprehensive analysis of smart bioelectronic systems in regenerative medicine.Missing: 2025 | Show results with:2025
  119. [119]
    From lab to life: how wearable devices can improve health equity - NIH
    Jan 2, 2024 · Medical wearables, non-invasive devices that measure physiological biomarkers, are potentially disruptive and powerful tools to promote health equity at scale.